The latest price target for Predictive Oncology (NASDAQ:POAI) was reported by HC Wainwright & Co. on November 15, 2024. The analyst firm set a price target for $0.00 expecting POAI to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Predictive Oncology (NASDAQ:POAI) was provided by HC Wainwright & Co., and Predictive Oncology downgraded their neutral rating.

There is no last upgrade for Predictive Oncology

The last downgrade for Predictive Oncology Inc happened on November 15, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Predictive Oncology Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Predictive Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Predictive Oncology was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest Predictive Oncology (POAI) rating was a downgraded with a price target of $0.00 to $0.00. The current price Predictive Oncology (POAI) is trading at is $0.86, which is out of the analyst’s predicted range.